List view / Grid view
3 October 2013 | By Celgene
Psoriasis of the scalp, another difficult-to-treat area, was also improved by treatment with apremilast 30 mg BID...
AbbVie (NYSE: ABBV) today announced results from a post-hoc analysis of an investigational Phase II study, which evaluated HUMIRA® (adalimumab) in the treatment of patients with moderate-to-severe hidradenitis suppurativa (HS) after 16 weeks of therapy.1
3 October 2013 | By Johnson & Johnson
Collaborations announced between regional innovators and Johnson & Johnson family of companies...
3 October 2013 | By Teva Pharmaceutical Industries Ltd
Teva believes unpredictable differences between a proposed generic product and COPAXONE® could lead to immunogenic effects in patients...
3 October 2013 | By Teva Pharmaceutical Industries Ltd
“To our knowledge, glatiramer acetate is the only treatment for multiple sclerosis that has been prospectively studied for nearly two decades..."
3 October 2013 | By Novartis
"Controlling relapses and preventing disability are key treatment goals for patients with MS..."
2 October 2013 | By AstraZeneca
AstraZeneca announced that the US Court of Appeals for the Federal Circuit (CAFC) lifted a temporary injunction against the US launch of Hanmi's 505(b)2 NDA esomeprazole strontium product...
2 October 2013 | By AstraZeneca
Hanmi’s launch would be at risk of owing AstraZeneca patent-infringement damages...
1 October 2013 | By biogen idec
Analyses reinforce efficacy of PLEGRIDY, further supporting a potential new treatment option for people with multiple sclerosis...
1 October 2013 | By AstraZeneca
The growth of the BioHub complements the work of the Alderley Park taskforce to capitalise and build on the existing local bioscience network and expertise...
1 October 2013 | By Amgen
"Amgen's acquisition of Onyx fits perfectly with our commitment to advancing medicines for cancer patients around the world..."
1 October 2013 | By Johnson & Johnson
“Everyone needs a complete eye exam because that’s how you are more likely to prevent blindness and eye disease..."
1 October 2013 | By Teva Pharmaceutical Industries Ltd
"This Phase III sub-study was pre-planned to explore the ability of laquinimod to act on mechanisms leading to irreversible brain tissue damage..."
1 October 2013 | By Roche
Leading scientists join together to discuss breakthrough research that addresses serious medical needs...
1 October 2013 | By Novartis
Data from head-to-head pivotal study showing secukinumab (AIN457) superiority to Enbrel®* (etanercept) in moderate-to-severe plaque psoriasis to be revealed...
